Among 11,093 hospitalized patients with cardiovascular diseases, the overall prevalence of comorbid cancer was 8.94%, showing a gradual increase over the 2011-2018 observational period.
Cohort (n=11,093)
No
The prevalence of cancer in hospitalized cardiovascular disease patients is approximately 9% and is gradually increasing, highlighting the growing importance of onco-cardiology.
BACKGROUND: Recent progress of cancer therapy has increased the number of cancer survivors, in whom cardiovascular diseases (CVDs) have become a big concern. This study aimed to clarify the prevalence of various types of CVDs in cancer patients, using the database of the Cardiovascular Medicine in Kurume University Hospital. METHODS AND RESULTS: This retrospective cohort study enrolled 11,093 hospitalized patients in Cardiovascular Medicine, Kurume University Hospital from April 2011 to March 2019. Among 11,093 enrolled patients, there were 992 CVDs patients with cancer (8.94%). The five most prevalent forms of cancer were colon cancer, prostate cancer, hepatocellular carcinoma, lung cancer, and gastric cancer. Although there was no statistical significance, the comorbidity of breast cancer gradually increased during the study period (2011-2018). In all CVDs, prostate cancer, lung cancer, and uterine cancer tended to increase as comorbidities, while hepatocellular carcinoma and tongue cancer tended to decrease during the observational period. The absolute number of patients with cancer increased in all CVDs, including coronary artery diseases, heart failure, arrhythmia, and pulmonary hypertension. CONCLUSIONS: The present study demonstrates that the prevalence of cancer in hospitalized CVDs patients was around 10%, and is showing a tendency to increase. Thus, cancer may have substantial impacts on CVDs treatment.
Sun et al. (Thu,) conducted a cohort in Cardiovascular diseases (n=11,093). Among 11,093 hospitalized patients with cardiovascular diseases, the overall prevalence of comorbid cancer was 8.94%, showing a gradual increase over the 2011-2018 observational period.